Significant survival gains for neoadjuvant chemotherapy for high risk soft tissue sarcoma

Bookmark and Share
Published: 10 Oct 2016
Views: 1628
Dr Alessandro Gronchi - National Cancer Institute, Milan, Italy

Dr Gronchi presents, at a press conference at ESMO 2016, results from a trial assessing response of patients with advanced soft tissue sarcoma to adjuvant epirubicin plus ifosfamide compared to those receiving a tailored chemo regimen based on histology subgrouping

He reports significantly improved relapse-free survival and overall survival for patients receiving adjuvant chemo, thought notes the trial is a technical failure due to being powered for the histology-tailored sub types which did not show any benefit.

Dr Gronchi spoke further with ecancer about these results, and the story is reported in ecancer news here.